4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7122-7131

  Dexheimer, Thomas S ^a   Gediya, Lalji K ^b,c   Stephen, Andrew G ^d   Weidlich, Iwona ^d,f   Antony, Smitha ^a   Marchand, Christophe ^a   Interthal, Heidrun ^e   Nicklaus, Marc ^d   Fisher, Robert J ^d   Njar, Vincent C ^b,c   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4 PREGNEN 21 OL 3,20 DIONE 21 (4 BENZENESUFONATE); 4 PREGNEN 21 OL 3,20 DIONE 21 (4 BROMOBENZENESUFONATE); 4 PREGNEN 21 OL 3,20 DIONE 21 (4 CHLOROBENZENESUFONATE); 4 PREGNEN 21 OL 3,20 DIONE 21 (4 FLOUROBENZENESUFONATE); 4 PREGNEN 21 OL 3,20 DIONE 21 (4 METHYLBENZENESUFONATE); 4 PREGNEN 21 OL 3,20 DIONE 21 (4 NITROBENZENESUFONATE); NSC 88915; OLIGONUCLEOTIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROGESTERONE DERIVATIVE; TYROSYL DEOXYRIBONUCLEIC ACID PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CROSS REACTION; DRUG INHIBITION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; MOLECULAR DOCKING; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; AXONS; BENZENESULFONATES; CATALYTIC DOMAIN; DNA, SINGLE-STRANDED; ESTERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MODELS, MOLECULAR; MUTATION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PREGNENEDIONES; SPINOCEREBELLAR ATAXIAS; STEROIDS; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

EID: 70949099730     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901061s     Document Type: Article

References (54)

1. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
2. Pratesi, G.; Beretta, G. L.; Zunino, F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anti-Cancer Drugs 2004, 15, 545-552.
3. Takagi, K.; Dexheimer, T. S.; Redon, C.; Sordet, O.; Agama, K.; Lavielle, G.; Pierre, A.; Bates, S. E.; Pommier, Y. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol. Cancer Ther. 2007, 6, 3229-3238.
4. Kroep, J. R.; Gelderblom, H. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin. Invest. Drugs 2009, 18, 69-75.
5. Pommier, Y. DNA Topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 2009, 109, 2894-2902.
6. Pommier, Y.; Cushman, M. The indenoisoquinoline noncamtothecin topoisomerase I inhibitors: update and perspectives. Mol. Cancer Ther. 2009, 8, 1008-1014.
7. Teicher, B. A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75, 1262-1271.
8. Marchand, C.; Antony, S.; Kohn, K. W.; Cushman, M.; Ioanoviciu, A.; Staker, B. L.; Burgin, A. B.; Stewart, L.; Pommier, Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 2006, 5, 287-295.
9. Pommier, Y.; Cherfils, J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol. Sci. 2005, 28, 136-145.
10. Pommier, Y.; Barcelo, J. M.; Rao, V. A.; Sordet, O.; Jobson, A. G.; Thibaut, L.; Miao, Z. H.; Seiler, J. A.; Zhang, H.; Marchand, C.; Agama, K.; Nitiss, J. L.; Redon, C. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81, 179-229.
11. Pommier, Y.; Redon, C.; Rao, A.; Seiler, J. A.; Sordet, O.; Takemura, H.; Antony, S.; Meng, L.-H.; Liao, Z. Y.; Kohlhagen, G.; Zhang, H.; Kohn, K. W. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res. 2003, 532, 173-203.
12. Pourquier, P.; Pommier, Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 2001, 80, 189-216.
13. Pouliot, J. J.; Yao, K. C.; Robertson, C. A.; Nash, H. A. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 1999, 286, 552-555.
14. Yang, S. W.; Burgin, A. B., Jr.; Huizenga, B. N.; Robertson, C. A.; Yao, K. C.; Nash, H. A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11534-11539.
15. Interthal, H.; Chen, H. J.; Champoux, J. J. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J. Biol. Chem. 2005, 280, 36518-36528.
16. Inamdar, K. V.; Pouliot, J. J.; Zhou, T.; Lees-Miller, S. P.; Rasouli-Nia, A.; Povirk, L. F. Conversion of phosphoglycolate to phosphate termini on 3′ overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J. Biol. Chem. 2002, 277, 27162-27168.
17. El-Khamisy, S. F.; Saifi, G. M.; Weinfeld, M.; Johansson, F.; Helleday, T.; Lupski, J. R.; Caldecott, K. W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005, 434, 108-113.
18. El-Khamisy, S. F.; Hartsuiker, E.; Caldecott, K. W. TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA Repair 2007, 6, 1485-1495. (Pubitemid 47385401)
19. Interthal, H.; Chen, H. J.; Kehl-Fie, T. E.; Zotzmann, J.; Leppard, J. B.; Champoux, J. J. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 2005, 24, 2224-2233.
20. Miao, Z. H.; Agama, K.; Sordet, O.; Povirk, L.; Kohn, K. W.; Pommier, Y. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair 2006, 5, 1489-1494. (Pubitemid 44739452)
21. Hawkins, A. J.; Subler, M. A.; Akopiants, K.; Wiley, J. L.; Taylor, S. M.; Rice, A. C.; Windle, J. J.; Valerie, K.; Povirk, L. F. In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair 2009, 8, 654-663.
22. Zhou, T.; Lee, J. W.; Tatavarthi, H.; Lupski, J. R.; Valerie, K.; Povirk, L. F. Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res. 2005, 33, 289-297.
23. Hirano, R.; Interthal, H.; Huang, C.; Nakamura, T.; Deguchi, K.; Choi, K.; Bhattacharjee, M. B.; Arimura, K.; Umehara, F.; Izumo, S.; Northrop, J. L.; Salih, M. A.; Inoue, K.; Armstrong, D. L.; Champoux, J. J.; Takashima, H.; Boerkoel, C. F. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J. 2007, 26, 4732-4743.
24. Katyal, S.; el-Khamisy, S. F.; Russell, H. R.; Li, Y.; Ju, L.; Caldecott, K. W.; McKinnon, P. J. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J. 2007, 26, 4720-4731.
25. Barthelmes, H. U.; Habermeyer, M.; Christensen, M. O.; Mielke, C.; Interthal, H.; Pouliot, J. J.; Boege, F.; Marko, D. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J. Biol. Chem. 2004, 279, 55618-55625.
26. Nivens, M. C.; Felder, T.; Galloway, A. H.; Pena, M. M.; Pouliot, J. J.; Spencer, H. T. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase. Cancer Chemother. Pharmacol. 2004, 53, 107-115.
27. Liu, C.; Zhou, S.; Begum, S.; Sidransky, D.; Westra, W. H.; Brock, M.; Califano, J. A. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 2007, 55, 303-311.
28. Davies, D. R.; Interthal, H.; Champoux, J. J.; Hol, W. G. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J. Mol. Biol. 2002, 324, 917-932.
29. Davies, D. R.; Interthal, H.; Champoux, J. J.; Hol, W. G. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem. Biol. 2003, 10, 139-147.
30. Liao, Z.; Thibaut, L.; Jobson, A.; Pommier, Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol. Pharmacol. 2006, 70, 366-372.
31. Antony, S.; Marchand, C.; Stephen, A. G.; Thibaut, L.; Agama, K. K.; Fisher, R. J.; Pommier, Y. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res. 2007, 35, 4474-4484. (Pubitemid 47244598)
32. Marchand, C.; Lea, W. A.; Jadhav, A.; Dexheimer, T. S.; Austin, C. P.; Inglese, J.; Pommier, Y.; Simeonov, A. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol. Cancer Ther. 2009, 8, 240-248.
33. Dexheimer, T. S.; Antony, S.; Marchand, C.; Pommier, Y. Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anti-Cancer Agents Med Chem 2008, 8, 381-389. (Pubitemid 351761423)
34. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 2005, 48, 2972-2984.
35. Carroll, F. I.; Philip, A.; Ferguson, A. M.; Wall, M. F. Steroid derivatives of purine-6-(1H)-thione (1a-c). J. Heterocycl. Chem. 1968, 5, 805-811.
36. Simons, S. S.; Pons, M.; Johnson, D. F. R-Keto mesylate: a reactive, thiol-specific functional group. J. Org. Chem. 1980, 45, 3084-3088.
37. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
38. Mohamadi, N.; Richards, G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caulfield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
39. Raymond, A. C.; Staker, B. L.; Burgin, A. B., Jr. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1). J. Biol. Chem. 2005, 280, 22029-22035.
40. Pouliot, J. J.; Robertson, C. A.; Nash, H. A. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 2001, 6, 677-687.
41. Interthal, H.; Pouliot, J. J.; Champoux, J. J. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12009-12014.
42. Takashima, H.; Boerkoel, C. F.; John, J.; Saifi, G. M.; Salih, M. A.; Armstrong, D.; Mao, Y.; Quiocho, F. A.; Roa, B. B.; Nakagawa, M.; Stockton, D. W.; Lupski, J. R. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat. Genet. 2002, 32, 267-272.
43. Martin, L. P.; Hamilton, T. C.; Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14, 1291-1295.
44. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193-204.
45. Kennedy, R. D.; D'Andrea, A. D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 2006, 24, 3799-3808.
46. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917. (Pubitemid 40559005)
47. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921. (Pubitemid 40559006)
48. Jacob, D. A.; Bahra, M.; Langrehr, J. M.; Boas-Knoop, S.; Stefaniak, R.; Davis, J.; Schumacher, G.; Lippert, S.; Neumann, U. P. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J. Gastroenterol. Hepatol. 2007, 22, 738-748.
49. Smith, L. M.; Willmore, E.; Austin, C. A.; Curtin, N. J. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 2005, 11, 8449-8457.
50. Pommier, Y.; Barcelo, J.; Rao, V. A.; Sordet, O.; Jobson, A. G.; Thibaut, L.; Miao, Z.; Seiler, J.; Zhang, H.; Marchand, C.; Agama, K.; Redon, C. Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81, 179-229.
51. Vance, J. R.; Wilson, T. E. Repair of DNA strand breaks by the overlapping functions of lesion-specific and non-lesion-specific DNA 30 phosphatases. Mol. Cell. Biol. 2001, 21, 7191-7198.
52. Vance, J. R.; Wilson, T. E. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13669-13674.
53. Liu, C.; Pouliot, J. J.; Nash, H. A. The role of TDP1 from budding yeast in the repair of DNA damage. DNA Repair 2004, 3, 593-601.
54. Deng, C.; Brown, J. A.; You, D.; Brown, J. M. Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics 2005, 170, 591-600.